Time-limited therapy with the combination of venetoclax and obinutuzumab in the first-line treatment of chronic lymphocytic leukemia
2023
Abstract
Targeted oral therapy that affects the B-cell receptor and antipoptotic protein Bcl-2 signaling pathways has improved the prognosis of patients with chronic lymphocytic leukemia. Our case report describes the course of treatment of a 66-year-old woman with genetically unfavorable non-mutated immunoglobulin heavy chain genes, without TP53 dysfunction.